Streetbeat News

CYTO

Altamira Therapeutics Ltd.

Industry

Biotechnology

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Open

0.44

Mkt cap

1.7M

Volume

202K

High

0.50

P/E Ratio

0.25

52-wk high

17.20

Low

0.43

Div yield

N/A

52-wk low

0.40

Altamira Therapeutics has announced improvements in its RNA nanoparticle stability, is seeking partnerships for its AM-125 product in vertigo and CNS indications, and will switch its financial reporting from Swiss Francs to US Dollars.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 2:33 pm

The article highlights significant intraday movements in health care stocks on Thursday. Notable gainers include OneMedNet, Renovaro, Altamira Therapeutics, Purple Biotech, P3 Health Partners, and Qilian Intl Hldg Gr. On the losing side, SILO Pharma, Cue Health, Protagenic Therapeutics, Cytokinetics, SAB Biotherapeutics, and DermTech experienced declines.

Portfolio Pulse from Benzinga Insights

May 23, 2024 | 4:31 pm

Altamira Therapeutics shares are trading higher following the publication of highlights from its NASAR clinical trial with Bentrio nasal spray on the social media channels of the journal, 'Allergy.'

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 4:21 pm

Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares surged by 27.3% after the company announced positive results from its NASAR clinical trial for Bentrio nasal spray. The trial, which involved 100 patients, showed significant efficacy in reducing nasal symptoms. The results were shared on social media by the allergology journal 'Allergy,' leading to heavy trading volume.

Portfolio Pulse from Erica Kollmann

May 23, 2024 | 4:20 pm

Altamira Therapeutics has announced the publication of highlights from the NASAR clinical trial on the social media channels of Allergy. This news could impact the stock price of Altamira Therapeutics, which is listed under the ticker symbol CYTO.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 12:55 pm

Altamira Therapeutics has filed a provisional patent application for its OligoPhore nanoparticles, which use siRNA to target the p65 protein, a key player in cancer and inflammation treatment. This development could mark a significant advancement in therapeutic options for these conditions.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 1:00 pm

Altamira Therapeutics announced the publication of positive results from its Bentrio trial in seasonal allergic rhinitis in the Allergy journal. The study met its primary efficacy endpoint, showing improvement in nasal symptoms, health-related quality of life, and reduced need for relief medication. These outcomes support Altamira's plans for further international expansion.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 12:48 pm

In Monday's pre-market session, health care stocks showed significant movement. Adial Pharmaceuticals (ADIL) and NKGen Biotech (NKGN) led the gainers with over 30% increases in their stock prices, while Vaxxinity (VAXX) and Hepion Pharmaceuticals (HEPA) were among the top losers, with VAXX stock dropping over 60%. The movements were attributed to various factors, including recent earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:07 pm

Altamira Therapeutics (NASDAQ:CYTO) reported a significant reduction in its quarterly losses to $(16.47) per share from $(629.80) per share YoY, alongside a decrease in sales to $284.47K from $330.37K.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 1:21 pm

Altamira Therapeutics reported a significant improvement in its fiscal year GAAP EPS, moving from CHF(409.60) to CHF(14.80) year-over-year. Additionally, the company's other operating income increased from CHF9.33K to CHF255.59K over the same period.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.